Licensed Technologies
Equilibra Bioscience
Based on an OMRF discovery, Equilibra Bioscience is developing a drug for the treatment of genetic bleeding disorders, Hemophilia A and Hemophilia B. The drug is currently in phase 1 clinical trials.
Otologic Pharmaceutics
Joint research from OMRF and Hough Ear Institute related to preventing and treating hearing loss is being advanced by Auditus, a wholly owned subsidiary of Otologic Pharmaceutics.
Q BioMed
Q BioMed, Inc. is a biotech acceleration and commercial stage company licensing Uttroside-B technology, and pursuing it as a new treatment of liver cancer. Uttroside-B is the product of joint research between OMRF and Rajiv Gandhi Centre for Biotechnology.
Oblato
OKN-007, a drug discovered at OMRF is being developed by Oblato for treatment of brain cancers. Clinical trials investigating the safety and efficacy of OKN-007 are ongoing.
FDA-Approved Drugs
Adakveo
Originating from an OMRF discovery, this drug is the first targeted therapy approved for the treatment of the pain crises in sickle cell disease. Early development was led by Selexys Pharmaceuticals, which was later acquired by Novartis in a transaction valued at up to $665 million.
Soliris
OMRF scientists made the seminal discovery that led to the development of Soliris, a first-in-class treatment for the blood disorder Paroxysmal Nocturnal Hemoglobinuria (PNH). Soliris was initially developed and marketed by Alexion Pharmaceuticals, which was acquired by AstraZeneca in 2020.
Ceprotin
Created from an OMRF discovery, this therapy from Baxter is a plasma-derived Protein C concentrate for use in patients with severe congenital Protein C deficiency. The product is currently marketed by Takeda Pharmaceuticals.
Diagnostic Tests
These technologies are available for commercial partnerships.
Crescendo
Founded on OMRF technology, Crescendo was a molecular diagnostics company focused on assessing disease activity and treatment response in rheumatoid arthritis. Its flagship product, Vectra® DA, became a widely adopted blood test for evaluating disease activity, leading to the company’s acquisition by Myriad Genetics for $270 million. The test, now known as Vectra®, is currently marketed by the diagnostic company Labcorp after it acquired Myriad Genetics’ autoimmune business unit in 2021.
Progentec Diagnostics
Progentec is an OMRF spinout developing biomarker–based tests (aiSLE® DX) that improve lupus diagnosis and management. Two of their aiSLE® DX tests are now available to clinicians. The aiSLE® DX Flare Risk Index provides clinicians with insight into a patient’s risk of an imminent flare, and the aiSLE® DX Disease Activity Index aids in assessing disease activity and assessment of treatment options.
Contact Tech Ventures
Visiting Us: OMRF Office of Technology Ventures is located on the first floor of the Bell Building, Room 105 across from McMechan Park.
MS #52
825 NE 13th St.
Oklahoma City, OK 73104
Hemangi Pakala, Ph.D.
Read Bio
Simanti Das, Ph.D.
Read Bio
John Miller
Read Bio
John Miller earned a bachelor’s degree in accounting and business management in 2013 and a MBA in 2015 from Oklahoma Christian University. John joined OMRF’s Office of Technology Ventures team as an operations assistant in 2019 where he manages finances and records related to agreements and patents and works on government reporting.
